Deconvoluting the complexity of autophagy in colorectal cancer: From crucial pathways to targeted therapies

Colorectal cancer (CRC) is a common gastrointestinal tumor with a high degree of malignancy, and most clinical cases are diagnosed at an advanced stage, which has unfortunately missed an opportunity for surgery; therefore, elucidation of the crucial pathways of CRC development and discovery of targe...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 12; p. 1007509
Main Authors Qiang, Liming, Li, Hongpeng, Wang, Zhaohui, Wan, Lin, Jiang, Guangfu
Format Journal Article
LanguageEnglish
Published Frontiers Media S.A 12.09.2022
Subjects
autophagy
colorectal cancer (CRC)
crucial pathway
Oncology
targeted therapy
therapeutic strategy
Online AccessGet full text

Cover

More Information
Summary:Colorectal cancer (CRC) is a common gastrointestinal tumor with a high degree of malignancy, and most clinical cases are diagnosed at an advanced stage, which has unfortunately missed an opportunity for surgery; therefore, elucidation of the crucial pathways of CRC development and discovery of targeted therapeutic strategies should be anticipated. Autophagy, which is an evolutionarily highly conserved catabolic process, may promote tumorigenesis and development of CRC. On the contrary, autophagy can trigger programmed cell death to inhibit CRC progression. Correspondingly, several targeted therapeutic strategies have been reported in CRC, including small-molecule compounds, polypeptides, non-coding RNAs, photodynamic, and adjuvant therapies. Thus, in this review, we focus on summarizing the crucial pathways of autophagy in CRC, and further discuss the current therapeutic strategies targeting autophagy. Together, these findings may shed light on the key regulatory mechanisms of autophagy and provide more promising therapeutic approaches for the future CRC therapies.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Reviewed by: Lingjuan Zhu, Shenyang Pharmaceutical University, China; Haiyang Yu, Tianjin University of Traditional Chinese Medicine, China
These authors have contributed equally to this work
This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Oncology
Edited by: Bo Liu, Sichuan University, China
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2022.1007509